-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascletis reports Phase I data for ASC47 obesity drug at ECO 2026

PUBT·05/06/2026 00:00:45
Listen to the news
Ascletis reports Phase I data for ASC47 obesity drug at ECO 2026
  • Ascletis Pharma announced it will present new posters at European Congress on Obesity (ECO 2026) in Istanbul on May 12-15, 2026, including first-in-human Phase I results for obesity candidate ASC47.
  • Early clinical findings showed ASC47 combined with semaglutide delivered greater weight loss than semaglutide alone, supporting a combination strategy aimed at weight reduction while preserving muscle.
  • Preclinical data to be presented for once-monthly obesity peptides ASC36 and ASC35 indicated longer-lasting activity than established comparators, with stronger weight-loss effects in animal models.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260506-12147142), on May 06, 2026, and is solely responsible for the information contained therein.